trending Market Intelligence /marketintelligence/en/news-insights/trending/HySjpL7Mto5f3NSfE4QIng2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

PerkinElmer's kit gets FDA nod as 1st test to screen rare disorder in newborns

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

PerkinElmer's kit gets FDA nod as 1st test to screen rare disorder in newborns

PerkinElmer Inc.'s kit to screen for a rare genetic disorder has been approved by the U.S. Food and Drug Administration, the first of its kind to test for Duchenne muscular dystrophy in newborns.

The U.S. regulator said the GSP Neonatal Creatine Kinase-MM kit can now be used by laboratories as part of a newborn screening panel to test for Duchenne muscular dystrophy, according to a Dec. 12 release.

Duchenne muscular dystrophy is characterized by progressive muscle degeneration and weakness, and is caused by the absence of a protein called dystrophin. The disease, which mainly affects boys, shows its symptoms in early childhood.

PerkinElmer's test measures the concentration of a specific protein in the blood called CK-MM, which increases when muscle damage occurs.

Higher levels of CK-MM may indicate the presence of Duchenne muscular dystrophy, the FDA said. The kit cannot be used for a definitive diagnosis of the disorder and results must be confirmed through other methods such as muscle biopsies and genetic tests.

The kit was evaluated under the FDA's de novo premarket review pathway, which allows submission for regulatory approval of novel, low-to-moderate-risk devices of a new type. The agency also established criteria outlining requirements for the verification, design validation and labeling for tests of this type.

Waltham, Mass.-based PerkinElmer provides solutions to the diagnostics, life sciences and applied services markets worldwide.